نتائج البحث - "Barry R, Davies"

1

AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia

المصدر: Clinical Cancer Research. 26:6535-6549

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::564420d79c6feacf9af617f03b6937bcTest
https://doi.org/10.1158/1078-0432.ccr-20-0863Test

2

BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population

المساهمون: Institut Català de la Salut, [Turner NC] Breast Unit, The Royal Marsden NHS Foundation Trust, London, UK. Breast Cancer Now Research Centre, The Institute of Cancer Research, London, UK. [Alarcón E] Clinical Oncology Department, British American Hospital, Lima, Peru. [Armstrong AC] Department of Medical Oncology, Christie Hospital NHS Foundation Trust and Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. [Philco M] Peruvian Institute of Oncology Radiotherapy, Lima, Peru. [López Chuken YA] University Hospital, Monterrey, Mexico. [Sablin MP] Department of Drug Development and Innovation (D3i), Curie Institute, Paris, France. [Oliveira, M] Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, Hospital Universitari Vall d'Hebron

المصدر: Scientia
Recercat. Dipósit de la Recerca de Catalunya
instname
Annals of oncology : official journal of the European Society for Medical Oncology
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
Annals of Oncology
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)

مصطلحات موضوعية: 0301 basic medicine, Oncology, Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES], Estrogen receptor, aminoácidos, péptidos y proteínas::proteínas::receptores citoplásmicos y nucleares::receptores de esteroides::receptores de estrógenos [COMPUESTOS QUÍMICOS Y DROGAS], Other subheadings::Other subheadings::/drug therapy [Other subheadings], AKT inhibitor, ER+, chemistry.chemical_compound, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Breast Tumors, Neoplasm Metastasis, education.field_of_study, neoplasias::neoplasias por localización::neoplasias de la mama [ENFERMEDADES], Neoplasms::Neoplastic Processes::Neoplasm Metastasis [DISEASES], Hematology, Metastatic breast cancer, Survival Rate, Receptors, Estrogen, Paclitaxel, Tolerability, 030220 oncology & carcinogenesis, Female, metastatic breast cancer, medicine.medical_specialty, Class I Phosphatidylinositol 3-Kinases, Population, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Breast Neoplasms, capivasertib, 03 medical and health sciences, Breast cancer, Double-Blind Method, Metàstasi, Internal medicine, Biomarkers, Tumor, medicine, Humans, Pyrroles, education, Survival rate, neoplasms, business.industry, Amino Acids, Peptides, and Proteins::Proteins::Receptors, Cytoplasmic and Nuclear::Receptors, Steroid::Receptors, Estrogen [CHEMICALS AND DRUGS], Cancer, HER2−, Original Articles, PIK3CA, medicine.disease, Pyrimidines, 030104 developmental biology, chemistry, Estrògens - Receptors, neoplasias::procesos neoplásicos::metástasis neoplásica [ENFERMEDADES], Mutation, Mama - Càncer - Tractament, Neoplasm Recurrence, Local, business, Proto-Oncogene Proteins c-akt